POPULARITY
Featuring perspectives from Dr Evan J Lipson, including the following topics: Introduction: Johns Hopkins University (0:00) Metastatic Melanoma (8:21) Nonmetastatic Melanoma and Other Skin Cancers (34:20) CME information and select publications
Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers.
Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Skin).
Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immunotherapy-focused treatment plans for appropriate patients with advanced melanoma to optimize long-term patient outcomes.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 2: Localized Melanoma and Other Types of Skin Cancer — Evan J Lipson, MD CME information and select publications
Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson, including the following topics: Introduction: Immunology of Melanoma (0:00) Melanoma (8:26) Cutaneous Squamous Cell Carcinoma (43:15) Basal Cell Carcinoma and Merkel Cell Carcinoma (52:55) CME information and select publications
Featuring a discussion on the most impactful updates from 2022 in the management of melanoma and nonmelanoma skin cancers with Dr Omid Hamid and Dr Evan J Lipson, moderated by Dr Neil Love.
Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.researchtopractice.com/YiR2022/SkinCancers).
Featuring perspectives from Dr Jason Luke, including the following topics: Introduction (0:00) DREAMseq Phase III Study (3:03) Case: A woman in her mid-50s with metastatic melanoma and a BRAF V600K mutation — Evan J Lipson, MD (18:08) Case: A man in his mid-60s with metastatic melanoma and a BRAF V600E mutation — Raji Shameem, MD (22:23) Case: A man in his late 60s with metastatic melanoma and a BRAF V600K mutation — Syed F Zafar, MD (33:04) Case: A man in his late 70s with melanoma and a history of transient ischemic attacks — Elizabeth Guancial, MD (37:39) Case: A man in his late 40s with resectable melanoma — Dr Lipson (42:38) Case: A man in his mid-50s with metastatic melanoma and a BRAF mutation — Allan Freedman, MD (46:08) Journal Club with Dr Luke (49:49) Beyond the Guidelines (52:39) CME information and select publications
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
This podcast is led by ASCO member, Evan J. Lipson, MD. Dr. Lipson recently launched a website, called Seize the Days, that offers people with cancer and their families an opportunity to record and preserve audio interviews as a way to share their personal stories with others. In this podcast, Dr. Lipson discusses Seize the Days and provides stories from patients about how a cancer diagnosis affected their lives. ASCO would like to thank Dr. Lipson and his patients for sharing these stories. Quality of Life